The Study of Decitabine Effect on the Endometrial Carcinoma Xenografted in Nude Mice
Abstract
To explore the effect of the demethylation drug 5-Aza-CdR on endometrial carcinoma xenografted in nude mice. Methods Randomly assigned the mice into decitabine (AZA), cisplatin (DDP), medroxyprogesterone acetate (MPA), AZA+DDP, AZA+MPA, DDP+MPA and model groups (three in each group) after building the models of xenografted tumor by transplanting the HEC-1B cells on nude mice, and dealt them respectively with corresponding drugs (1 μg/g, single or combination) in the experiment groups and normal saline in model group (injected per 3 d, 8 injections in total). Then the tumor inhibitory rates in different groups were calculated. The methylation and protein expression of RASSF1A gene was estimated by methylation specific PCR (MSP) and Western blot respectively, and apoptosis situation of carcinoma cell was estimated by tunel. Results Inhibitory rate in AZA + DDP group was the highest, and the lowest was AZA group. RASSF1A gene promoter region methylation levels of AZA, AZA + DDP and AZA + MPA groups significantly reduced and showed obvious demethylation stripes while other groups mainly showed the methylation stripes. The differences of RASSF1A protein expression between AZA, AZA + DDP and AZA + MPA groups were not statistical significant (P>0.05), but the three were higher than model group (P<0.05); there was no statistically significant difference respectively in the DDP, MPA, DDP + MPA groups compared with that of model group (P>0.05). In the comparison of apoptosis index, model group was the lowest, followed by the three single medicine groups, and the highest was three combination groups (P<0.05). Conclusion Demethylation drug 5-Aza-CdR in endometrial cancer treatment has a great potential clinical application value by reversing the abnormal methylation of RASSF1A gene, restoring biological functions of RASSF1A protein and strengthening the efficacy of DDP and MPA.
Keywords: Decitabine, Xenografted tumor endometrial carcinoma, Demethylation, RASSF1A gene
Full Text:
PDFReferences
LYKO F. BROWN R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. Nat Cancer Inst. 2005.97(20): 1498-1506.
ISSAJP. KANTARJIAN HM, KIRKPATRICK P. Azacitidine. Nat Rev Drug Discov.2005.4(4) :275-276.
DAMMANNR. LI C. YOON JH. et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21. 3. Nat Genet, 2000, 25(3):315-319.
NEPHEW KP, HUANG TH. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett, 2003, 190( 2): 125-133.
ZHANG QY, ZHOU L, ZHANG DH, et al. Frequency and significance of CpG island methylator phenotype in endometrial cancer. Pract J Cancer,2010,25(3);247-251.
PALLARES J, VELASCO A, ERITJA N. Promotor hypermetylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Modern Pathol,2008,21 (6) ;691-699.
SHENG Y, WANG H. LIU D,et al. Methylation of tumor suppressor gene CD И13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma. Gynecol Oncol. 2016, 140 ( 1 ); 145- 151.
YU CG, JIANG XY. LI B, etal. Expression of ER, PR. C- erbB-2 and Ki-67 in endometrial carcinoma and their relationships with the clinicopathological features. Asian Рас J Cancer Prev,2015,16( 15) :6789-9671.
USHIJIMA К. YAHATA H, YOSHIKAWA H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol,2007,25 (19):2798-2803.
YANG S. THIEL KW, DE GEEST K,et al. Endometrial cancer; reviving progesterone therapy in the molecular age. Discov Med ,2011 ,12(64): 205-212.
KIM JJ, KURITA T, BULUN SE. Progesterone action in endometrial cancer, endometriosis* uterine fibroids, and breast cancer. Endocr Rev,2013,34(1); 130-162.
SHAO R. Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma. Ecancermedicalscience, 2013 ( 7 ): 381 [ 2015-09-19 ]. https://www. ncbi. nlm. nih. gov/pmc/articles/PMC3869473/. doi; 10. 3332/ecancer. 2013.381.
Refbacks
- There are currently no refbacks.
